GlassScriptPhysician profile
Roger Kirkwood
NPI 1063728764
$5,609.10
in general payments reported to CMS, 2019-2025
18 companies · $2,996 in 2025
The $2,996 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $308 · 2022: $187 · 2023: $1,498 · 2024: $621 · 2025: $2,996.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,899 · Travel and Lodging: $1,079 · Education: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,898.62 |
| Travel and Lodging | $1,079.48 |
| Education | $136.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,569.64 | 2023-2025 | Spravato |
| Abbvie INC. | $928.09 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $523.51 | 2022-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $441.15 | 2021-2023 | Austedo Xr, Austedo |
| Axsome Therapeutics, INC. | $399.63 | 2023-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $319.21 | 2022-2025 | Qelbree |
| Alkermes, INC. | $301.15 | 2023-2025 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $216.14 | 2021-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $200.04 | 2021-2023 | |
| Lundbeck LLC | $159.85 | 2022-2025 | Rexulti |
| Collegium Pharmaceutical, INC. | $155.83 | 2025 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $121.71 | 2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $79.91 | 2022-2025 | Ingrezza |
| Janssen Scientific Affairs, LLC | $68.43 | 2025 | Spravato |
| Tris Pharma INC | $54.30 | 2023-2024 | Dyanavel Xr |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $36.74 | 2023-2024 | Adzenys Xr-Odt |
| Corium, LLC | $22.64 | 2023 | Azstarys |
| Vanda Pharmaceuticals INC. | $11.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Kirkwood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.